Catalyst Event
Astrazeneca PLC (AZN) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
4/28/2026, 12:00:00 AM
The U.S. FDA approved Breztri Aerosphere for the maintenance treatment of asthma in patients aged 12 and older on 2026-04-28. This is the second indication for Breztri, which was previously approved for COPD.
Korean Translation
2026년 4월 28일 미국 FDA, 12세 이상 환자의 천식 유지 요법으로 브레즈트리 에어로스피어(Breztri Aerosphere)를 승인함. 이는 만성 폐쇄성 폐질환(COPD)에 이어 브레즈트리의 두 번째 적응증 승인임.
Related Recent Events
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 fiscal 2027 earnings release is scheduled for May 20, 2026. Low importance assigned as the announcement of an earnings date typically results in ~1% price impact, scheduled.
5/20/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Earnings Release
First quarter 2026 financial results and conference call on May 11, 2026, with high importance estimated due to potential market impact of earnings guidance, scheduled.
5/11/2026, 12:00:00 AM
Caris Life Sciences Inc (CAI) · Earnings Release
First quarter 2026 financial results on May 7, 2026, to be released after market close; significant price impact expected based on recent growth trends scheduled.
5/7/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Natera is expected to announce its Q1 2026 financial results scheduled. Scheduled earnings releases are key volatility events with an estimated 5% impact.
5/7/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
First quarter 2026 financial results and business update scheduled for May 5, 2026; high impact from potential 10% price volatility expected.
5/5/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
BioNTech will report first-quarter 2026 financial results and provide a corporate update on 2026-05-05; given the sharp March 2026 volatility after guidance and leadership news, this update is likely to be closely watched and could move shares materially, expected.
5/5/2026, 12:00:00 AM